D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 101 Citations 42,589 450 World Ranking 3565 National Ranking 2035

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

Walter M. Stadler mainly focuses on Internal medicine, Surgery, Renal cell carcinoma, Carcinoma and Oncology. Internal medicine is frequently linked to Gastroenterology in his study. His work carried out in the field of Surgery brings together such families of science as Placebo, Kidney cancer, Prostate cancer and Urology.

The study incorporates disciplines such as Progression-free survival, Kidney disease and MAPK/ERK pathway in addition to Renal cell carcinoma. His Carcinoma research incorporates elements of Transitional cell carcinoma, Urinary system and Prospective cohort study. His research in Oncology intersects with topics in Bladder cancer, Gynecology, Erlotinib, Fludarabine and Transplantation.

His most cited work include:

  • Sorafenib in advanced clear-cell renal-cell carcinoma. (4025 citations)
  • Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (939 citations)
  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (907 citations)

What are the main themes of his work throughout his whole career to date?

Walter M. Stadler mostly deals with Internal medicine, Oncology, Surgery, Renal cell carcinoma and Prostate cancer. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His work on Sunitinib as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science.

His studies deal with areas such as Placebo and Urology as well as Surgery. His study in Renal cell carcinoma is interdisciplinary in nature, drawing from both Nivolumab and Carcinoma. He works mostly in the field of Prostate cancer, limiting it down to topics relating to Cancer research and, in certain cases, Immunology, Pathology and Endocrinology.

He most often published in these fields:

  • Internal medicine (65.19%)
  • Oncology (49.26%)
  • Surgery (27.04%)

What were the highlights of his more recent work (between 2014-2021)?

  • Internal medicine (65.19%)
  • Oncology (49.26%)
  • Renal cell carcinoma (22.96%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Oncology, Renal cell carcinoma, Prostate cancer and Phases of clinical research. His research on Internal medicine frequently connects to adjacent areas such as Surgery. His Surgery study combines topics in areas such as Gastroenterology and Cohort.

His Oncology research includes themes of Bevacizumab, Placebo and Clinical trial, Pathology. His studies in Renal cell carcinoma integrate themes in fields like Nivolumab, Carcinoma, Systemic therapy and Urology. His work on Castration resistant, Enzalutamide and Androgen receptor as part of general Prostate cancer study is frequently linked to Veliparib, bridging the gap between disciplines.

Between 2014 and 2021, his most popular works were:

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 (506 citations)
  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (385 citations)
  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial (328 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Walter M. Stadler spends much of his time researching Internal medicine, Oncology, Renal cell carcinoma, Sunitinib and Prostate cancer. His work deals with themes such as Gastroenterology, Surgery and Pathology, which intersect with Internal medicine. His Oncology study integrates concerns from other disciplines, such as Cancer, Gemcitabine, Clinical trial and Metastatic Urothelial Carcinoma.

His Renal cell carcinoma research is multidisciplinary, incorporating perspectives in Nivolumab, Carcinoma and Urology. His biological study spans a wide range of topics, including Bevacizumab, Randomized controlled trial, Atezolizumab and Clear cell renal cell carcinoma. His Androgen receptor study, which is part of a larger body of work in Prostate cancer, is frequently linked to Veliparib, bridging the gap between disciplines.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Sorafenib in advanced clear-cell renal-cell carcinoma.

Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik.
The New England Journal of Medicine (2007)

5608 Citations

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik.
Journal of Clinical Oncology (2009)

1271 Citations

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty.
Journal of Clinical Oncology (2006)

1269 Citations

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan.
Journal of Clinical Oncology (2004)

1150 Citations

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler.
Journal of Clinical Oncology (2008)

1070 Citations

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler.
Journal of Clinical Oncology (2010)

922 Citations

Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ezra E. W. Cohen;Fred Rosen;Walter M. Stadler;Wendy Recant.
Journal of Clinical Oncology (2003)

750 Citations

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler.
Journal of Clinical Oncology (2004)

676 Citations

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano.
Journal of Clinical Oncology (2016)

660 Citations

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Hedy L. Kindler;Gregory Friberg;Deepti A. Singh;Gershon Locker.
Journal of Clinical Oncology (2005)

600 Citations

Best Scientists Citing Walter M. Stadler

Toni K. Choueiri

Toni K. Choueiri

Harvard University

Publications: 224

Bernard Escudier

Bernard Escudier

Institut Gustave Roussy

Publications: 204

Brian I. Rini

Brian I. Rini

Vanderbilt University Medical Center

Publications: 195

Robert J. Motzer

Robert J. Motzer

Memorial Sloan Kettering Cancer Center

Publications: 168

Joaquim Bellmunt

Joaquim Bellmunt

Beth Israel Deaconess Medical Center

Publications: 164

Cora N. Sternberg

Cora N. Sternberg

Cornell University

Publications: 138

Johann S. de Bono

Johann S. de Bono

Institute of Cancer Research

Publications: 109

David F. McDermott

David F. McDermott

Beth Israel Deaconess Medical Center

Publications: 104

Alain Ravaud

Alain Ravaud

University of Bordeaux

Publications: 103

Ronald M. Bukowski

Ronald M. Bukowski

Cleveland Clinic

Publications: 95

Nicholas J. Vogelzang

Nicholas J. Vogelzang

University of Nevada Reno

Publications: 94

Thomas E. Hutson

Thomas E. Hutson

Texas Oncology

Publications: 92

Shahrokh F. Shariat

Shahrokh F. Shariat

Medical University of Vienna

Publications: 91

Thomas Powles

Thomas Powles

Queen Mary University of London

Publications: 91

Nizar M. Tannir

Nizar M. Tannir

The University of Texas MD Anderson Cancer Center

Publications: 82

Eric J. Small

Eric J. Small

University of California, San Francisco

Publications: 78

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.